XBiotech Stands By Advanced Colorectal Cancer Phase III Study
Executive Summary
The Austin, Texas-based biotech XBiotech has stood by its clinical trial strategy in critically-ill colorectal cancer patients, that could lead to the relatively rapid assessment of cancer agents in this group of patients, including the assessment of its lead product, the anti-IL-1 alpha monoclonal antibody, Xilonix.
You may also be interested in...
XBiotech Says CHMP ‘No’ Was A Surprise, Despite The Signs
Where now for XBiotech? The US firm says that despite a big setback for Xilonix in the EU, it will continue to develop the product in oncology.
I-SPY 2 Helping To Normalize Adaptive Trial Designs
Publication in NEJM of results from Phase II of master protocol study of breast cancer combinations also helps build support for Bayesian statistics.
PIPELINE WATCH - Eight Approvals, Seven Filings And Four Launches
This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.